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Objectives. We hypothesized that L-arginine would improve
abnormal coronary vasodilation in response to physiologic stress
in patients with atherosclerosis and its risk factors by reversing
coronary endothelial dysfunction.
Background. Studies have demonstrated that physiologic coro-
nary vasodilation correlates with endothelial function and that
L-arginine, the substrate for nitric oxide synthesis, improves the
response to acetylcholine (Ach).
Methods. Changes in coronary blood flow and epicardial diam-
eter response to Ach, adenosine and cardiac pacing were mea-
sured in 32 patients with coronary atherosclerosis or its risk
factors and in 7 patients without risk factors and normal coronary
angiograms.
Results. Intracoronary L-arginine did not alter baseline coro-
nary vascular tone, but the epicardial and microvascular re-
sponses to Ach were enhanced (both p < 0.001). The improvement
after L-arginine was greater in epicardial segments that initially
constricted with Ach; similarly, L-arginine abolished microvascu-
lar constriction produced by higher doses of Ach. Thus, there was
a negative correlation between the initial epicardial and vascular
resistance responses to Ach and the magnitude of improvement
with L-arginine (r 5 20.55 and r 5 20.50, respectively, p <
0.001). D-Arginine did not affect the responses to Ach, and
adenosine responses were unchanged with L-arginine. Cardiac
pacing-induced epicardial constriction was abolished by L-
arginine, but microvascular dilation remained unaffected.
Conclusions. Thus, L-arginine improved endothelium-dependent
coronary epicardial and microvascular function in patients with
endothelial dysfunction. Prevention of epicardial constriction
during physiologic stress by L-arginine in patients with endothe-
lial dysfunction may be of therapeutic value in the treatment of
myocardial ischemia.
(J Am Coll Cardiol 1997;30:1220–7)
©1997 by the American College of Cardiology
The vascular endothelium, by its tonic release of nitric oxide
(NO), plays a crucial role in smooth muscle vasodilation,
inhibition of thrombosis, regulation of cellular proliferation
and prevention of inflammation (1,2). Nitric oxide is synthe-
sized in the endothelial cell by the action of a constitutive
calcium-dependent enzyme, NO synthase, on L-arginine, which
is converted to citrulline and NO (3–6). Although sufficient
quantities of the substrate L-arginine are available in normal
endothelial cells even under maximal stimulation (7–9), in vivo
studies report restoration of abnormal endothelial function
with exogenous administration of L-arginine (10–22). Studies
in human coronary and peripheral circulations have, however,
yielded conflicting results; some have demonstrated improve-
ment in acetylcholine (Ach)-mediated forearm vasodilation
with L-arginine in normal individuals (14,16), whereas others
have elicited improvement only in the hypercholesterolemic
forearm and coronary circulations (11,13,21).
We have recently demonstrated that NO contributes to
coronary vasodilator tone at rest and modulates coronary
vasodilation during metabolic stress (23–25). Furthermore, this
contribution of NO to rest and metabolic vasodilator tone is
reduced in patients with risk factors for atherosclerosis and
those with established atherosclerosis. In this study, we hypoth-
esized that L-arginine would improve abnormal coronary va-
sodilation in response to physiologic stress in patients with
atherosclerosis and its risk factors by reversing coronary endo-
thelial dysfunction.
Methods
Patients. We studied 39 patients (25 men, 14 women), 24
with angiographically normal coronary arteries and 15 with
atherosclerosis on angiography, who were undergoing cardiac
catheterization for investigation of chest pain or abnormal
noninvasive tests (Table 1). Patients with moderately severe
left ventricular dysfunction (ejection fraction ,35%) and those
with valvular heart disease were excluded. Of the patients with
angiographically normal coronary arteries, 17 patients had one
or more of the following risk factors: hypercholesterolemia
(total cholesterol .250 mg/dl or high density lipoprotein
cholesterol ,30 mg/dl), hypertension (blood pressure
.140/90 mm Hg), diabetes or current smoking status, whereas
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the remaining seven patients did not have any risk factors for
atherosclerosis and were ,60 years old (Table 1). All cardiac
medications were withdrawn at least 48 h before the study, and
aspirin and other cyclooxygenase inhibitors were discontinued
for at least 7 days before the study.
Protocol (Fig. 1). After diagnostic coronary angiography, a
6F guide catheter was introduced into the proximal segment of
a major coronary artery, and blood flow velocity was measured
using an 0.018-in. (0.046-cm) wire equipped with a Doppler
crystal at its tip (Cardiometrics Flowire, Cardiometrics, Inc.)
(23–26). In patients with atherosclerosis, the Doppler wire was
placed in a coronary artery with ,30% narrowing of the lumen
to ensure that the flow changes represented changes in the
resistance microvessels and not in the caliber of the epicardial
stenosis. The wire tip was carefully positioned in a segment of
the vessel that was straight and free of any major branches
1 cm from the tip, which produced an adequate flow velocity
signal and could be imaged without overlap from other vessels,
thus allowing for quantitative measurements of the coronary
artery diameter. All drugs were infused directly into the left
main or right coronary arteries through the guide catheter at
infusion rates ranging between 1 and 2 ml/min.
After a 5-min infusion of 5% dextrose at 1 ml/min, baseline
coronary blood flow velocity measurements and coronary
angiography were performed. Cardiac pacing of the right
atrium or ventricle in 27 patients (mean heart rate 141 6 11
beats/min) for 2 min, and the measurements were repeated.
Endothelium-dependent vasodilation was estimated by per-
forming dose-response curves with incremental 2-min infu-
sions of intracoronary Ach. Acetylcholine was given at 30
mg/min, increasing to 100 and 300 mg/min (estimated intra-
coronary concentrations of 1026 mol/liter, 3.3 3 1026 mol/liter
and 1025 mol/liter) in patients with normal coronary arteries,
but was commenced at 3 mg/min (1027 mol/liter) in patients
with atherosclerosis. The dose of Ach was not increased
further once the infusion either reduced blood flow velocity or
severely narrowed (.50%) the epicardial coronary tree. Thus,
2 patients were given the 3-mg/min dose, 8 patients were given
doses up to 30 mg/min and 12 patients up to the 100-mg/min
dose, and 17 patients received up to 300 mg/min of Ach. All
infusions were given for 2 to 21⁄2 min.
Endothelium-independent function was estimated by ad-
ministration of intracoronary adenosine at 2.2 mg/min for
2 min in all patients.
After a 10-min interval, while continuing the 5% dextrose
infusion, repeat baseline measurements of flow velocity and
angiography were made. This was followed by a 10-min
infusion of 160 mmol/min of L-arginine.
While continuing the infusion of L-arginine at 160 mmol/
min, cardiac pacing was repeated for 2 min, followed by
administration of two peak doses of Ach (3-mg/min dose in 8
patients, 30-mg/min dose in 24 patients, 100-mg/min dose in 27
patients and 300-mg/min dose in 13 patients). Adenosine was
readministered in 23 patients. Blood flow velocity was mea-
sured and coronary angiography was performed after each
intervention.
After a 30-min period in six patients with atherosclerosis or
its risk factors, D-arginine, a stereoscopic isomer of L-arginine
that is not a substrate for NO synthesis (5), was given at 160
mmol/min for 10 min and one dose of Ach (30 mg/min in four
patients and 100 mg/min in two patients) was readministered.
The study was approved by the Institutional Review Board
of the National Heart, Lung, and Blood Institute.
Measurement of coronary blood flow and diameter. Coro-
nary blood flow was derived from the coronary blood flow
velocity and diameter measurements using the formula (p 3
average peak velocity 3 0.125 3 diameter2) (26). Coronary
vascular resistance was calculated as mean arterial pressure
divided by coronary blood flow. For calculating flow, coronary
artery diameter was measured in a 0.5-cm segment of vessel
beginning 0.25 cm beyond the tip of the Doppler wire. Coro-
nary angiograms were recorded using a cineangiographic sys-
tem (Toshiba, Inc.), and quantitative angiography was per-
Figure 1. Protocol design.
Table 1. Patient Characteristics
All
(n 5 39)
Pts With
Normal
Coronary
Arteries
(n 5 24)
Pts With
Coronary
Artery
Disease
(n 5 15)
Male 25 14 11
Age (yr) 56 6 10 54 6 10 58 6 10
Total cholesterol (mg/dl) 223 6 42 219 6 42 228 6 42
HDL cholesterol (mg/dl) 42 6 12 43 6 13 40 6 11
Hypertension 13 (33%) 7 (29%) 6 (40%)
Diabetes 6 (15%) 4 (17%) 2 (13%)
Current smokers 7 (18%) 3 (13%) 4 (27%)
Ex-smokers 15 (38%) 10 (42%) 5 (33%)
Data are presented as number (%) of patients or mean value 6 SD. HDL 5
high density lipoprotein; Pts 5 patients.
Abbreviations and Acronyms
Ach 5 acetylcholine
ANOVA 5 analysis of variance
NO 5 nitric oxide
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formed with the ARTEK software (Quantim 2001, Statview,
ImageComm Systems, Inc.).
In addition to the measurement of the diameter at the level
of the Doppler wire, a 0.5- to 1-cm distal region of the
epicardial coronary artery was also measured, whenever tech-
nically possible, by quantitative coronary angiography in all
patients. A total of 90 segments were measured in patients with
normal coronary arteries and 56 segments in patients with
coronary artery disease.
Statistical analysis. Data are expressed as mean value 6
SD in the text. All p values are two-tailed, and p , 0.05 was
considered statistically significant. The effects of L-arginine on
two doses of Ach were compared by using two-way analysis of
variance (ANOVA), which included patients, intervention
(control and L-arginine) and test (acetylcholine doses), and the
two-factor interactions between them. The interaction between
intervention and test had a p value .0.05. Correlations be-
tween the effects of Ach and L-arginine were made using the
Pearson correlation coefficient.
Multiple stepwise regression analyses (27) were performed
to test whether the magnitude of change with L-arginine at
each of the two doses of Ach in the microvascular or the
epicardial coronary arteries was related to age, gender, the
presence of hypertension, diabetes, cigarette use, total choles-
terol, high density lipoprotein cholesterol, triglyceride level or
to the initial response with Ach. Thus, four analyses were
performed—two for the change in vascular resistance with
each dose of Ach and two for the change in distal coronary
diameter at the two doses of Ach.
Results
Effect of L-arginine on rest coronary vascular tone. L-
Arginine infusion did not affect rest epicardial or microvascu-
lar tone. The mean coronary vascular resistance was 3.37 6
2.7 mm Hg/ml21 per min before and 3.29 6 2.7 mm Hg/ml21
per min 10 min after 160 mmol/min of L-arginine. Similarly,
both proximal and distal coronary diameters remained un-
changed (proximal: 2.7 6 0.66 mm before and 2.7 6 0.65 mm
after; distal: 1.64 6 0.35 mm before and 1.62 6 0.35 mm after).
There were no significant differences in the response to
L-arginine between patients with and without coronary athero-
sclerosis.
Effect of L-arginine on response to Ach. The effect of
L-arginine in all 39 patients at the two doses of Ach adminis-
tered is demonstrated in Figure 2. There was a significant
improvement in Ach-mediated microvascular and epicardial
coronary vascular changes after L-arginine. Compared with
baseline, coronary vascular resistance was 46% and 36% lower
at the two doses of Ach during the control study and 53% and
54% lower, respectively (p 5 0.013 by ANOVA) after L-
arginine. Similarly, both the proximal and distal segments of
the epicardial coronary arteries were larger after Ach and
L-arginine (p , 0.008 by ANOVA); the proximal coronary
diameter was 2.59 6 0.7 and 2.53 6 0.7 mm at the two doses
of Ach, and 2.71 6 0.6 and 2.64 6 0.7 mm after L-arginine and
Ach, respectively; and the distal coronary diameter was 1.58 6
0.5 and 1.54 6 0.6 mm at the two doses of Ach, and 1.63 6 0.5
and 1.61 6 0.5 mm after L-arginine and Ach, respectively.
In 22 patients, Ach produced maximal microvascular vaso-
dilation at the lower dose (mean 65 mg/min) and resulted in
vasoconstriction at the next higher dose (mean 200 mg/min), so
that coronary vascular resistance was higher at the second dose
of Ach compared with the initial dose (Fig. 3). In the remain-
ing patients with atherosclerosis, higher doses of acetylcholine
were not administered because of epicardial constriction.
L-Arginine produced significant improvement in microvascular
vasodilation only at the higher dose of Ach, and it abolished
the constriction observed during the control study (Fig. 3).
There was a significant negative correlation between the
change in coronary vascular resistance in response to Ach
during the control study and the change in resistance with Ach
during L-arginine (r 5 20.5, p 5 0.001), such that the
improvement with L-arginine was greater at doses of Ach that
produced microvascular constriction.
Similarly, epicardial coronary artery segments were divided
into those that dilated in response to Ach and those that
constricted. As demonstrated in Figure 3, there was less
constriction with L-arginine in segments that initially had an
abnormal (constrictor) response to Ach (mean 212.3 6 10%
before and 27.5 6 11% after L-arginine, p , 0.001); however,
Figure 2. Coronary vascular resistance and flow with Ach (n 5 39),
before (solid circles) and after (open circles) L-arginine administra-
tion. Results are expressed as mean value 6 SEM.
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segments that initially dilated with Ach did not dilate further
after L-arginine and Ach. Thus, there was a negative correla-
tion (r 5 20.55, p , 0.001) between the initial diameter
change with Ach and the change with Ach during L-arginine.
Relation between response to L-arginine and presence of
atherosclerosis or its risk factors. The impact of atheroscle-
rosis and risk factors for atherosclerosis, including age, gender,
total cholesterol, high density lipoprotein cholesterol and
triglyceride levels, the presence or absence of hypertension,
diabetes and smoking history, as well as the baseline response
to Ach, was examined on the subsequent epicardial or micro-
vascular response to L-arginine by multiple stepwise regression
analyses. These analyses were performed for the magnitude of
change in coronary vascular resistance and the distal diameter
at both doses of Ach. At both doses of Ach, the initial
microvascular response to Ach was the only independent
predictor of the magnitude of improvement with L-arginine
(p , 0.03). Similarly, the initial diameter response to Ach was
the only independent predictor of the subsequent change with
L-arginine at the low dose of Ach (p 5 0.001), and at the high
dose of Ach, both cigarette smoking (p 5 0.023) and the initial
diameter change with Ach (p 5 0.04) were independent
predictors.
Specificity of response to L-arginine. To investigate
whether the response to L-arginine was specifically due to its
property as a substrate for synthesis of NO, we studied the
effects of D-arginine on the response to Ach in patients with
atherosclerosis or its risk factors. Unlike the findings with
L-arginine, there was no effect of D-arginine on Ach-mediated
changes in coronary vascular resistance or epicardial diameter
(Fig. 4).
Effect of L-arginine on endothelium-independent vasodila-
tion. Coronary microvascular dilation with adenosine was
similar in patients without risk factors (278 6 7% reduction in
coronary vascular resistance), in those with normal coronary
arteries and risk factors (278 6 8%) and in those with
coronary artery disease (274 6 11%).
To determine whether the effects of L-arginine were specific
for endothelium-dependent dilators, we studied its action on
the coronary vascular effects of adenosine. The vascular resis-
tance with adenosine before and after L-arginine (0.69 6 0.44
and 0.68 6 0.38 mm Hg/ml21 per min, p 5 0.6) was similar,
and the coronary diameter (proximal diameter 3.0 6 0.67 and
3.04 6 0.63 mm, p 5 0.8) remained unchanged.
Figure 4. Coronary vascular resistance and flow and proximal and
distal coronary artery diameters with Ach before (solid circles) and
after (open circles) D-arginine administration. Results are expressed as
mean value 6 SEM.
Figure 3. Top, Coronary vascular resistance at the peak dilating and
constricting doses of Ach in 22 patients before (solid circles) and after
(open circles) L-arginine administration. Bottom, Effect of L-arginine
on epicardial coronary artery segments that initially constricted (left)
or dilated (right) with Ach. Results are expressed as mean value 6
SEM.
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Impact of L-arginine on metabolic coronary vasodilation.
Cardiac pacing in 27 patients produced a 25 6 23% decrease
in coronary vascular resistance and a 6 6 12% increase (both p ,
0.01) in epicardial coronary artery diameter. After L-arginine,
repeat cardiac pacing at a similar heart rate (141 6 11 beats/min)
resulted in no further increase in microvascular dilation (Fig. 5).
There was also no correlation between the magnitude of change
in coronary vascular resistance during cardiac pacing and the
subsequent response to L-arginine. The overall response of prox-
imal and distal segments of the epicardial coronary arteries to
L-arginine was also not significant. However, L-arginine abolished
pacing-induced constriction in segments that initially constricted
with cardiac pacing. In contrast, segments that initially dilated
with pacing did not change significantly with L-arginine (Fig. 5).
Thus, there was a negative correlation between the initial epicar-
dial response to metabolic stress and the magnitude of improve-
ment with L-arginine (r 5 20.49, p , 0.001).
Discussion
The major findings of our study are 1) intracoronary L-
arginine prevents Ach-mediated coronary epicardial and mi-
crovascular constriction; 2) this effect is specific for L-arginine,
as it did not occur with its stereoisomer, D-arginine, and
L-arginine did not improve vasodilation in response to the
endothelium-independent vasodilator adenosine; and 3) shear-
induced epicardial coronary constriction during cardiac pacing,
a sign of endothelial dysfunction, is abolished by L-arginine.
Mechanisms underlying the effects of L-arginine on
endothelium-dependent vasodilation. L-Arginine is the sub-
strate for endothelial NO synthesis, a reaction that is catalyzed
by the constitutive action of a calcium-calmodulin-dependent
enzyme, NO synthase (3–6). In normal vessels, there is suffi-
cient intracellular substrate present (0.8 to 2 mmol/liter) to
saturate NO synthase (Michaelis constant [Km] for L-arginine
is 2.9 mmol/liter) (7). When L-arginine levels are depleted in
vitro, exogenous L-arginine enhances endothelium-dependent
vasodilation, whereas in normal, nondepleted states, there is
no change in endothelium-dependent vasodilation with L-
arginine (12,28,29). However, the experimental kinetics of NO
synthase and L-arginine interactions do not explain several
animal and human in vivo studies demonstrating that admin-
istration of either parenteral or oral L-arginine improved
endothelium-dependent relaxation and promoted release of
NO (10–22). This discrepancy has been at least partly ad-
dressed by discovery of the regulatory role of physiologic levels
of L-glutamine in receptor-mediated NO release by interfering
with signal transduction (28,30). Thus, L-arginine may promote
NO release by reversing the inhibitory effects of L-glutamine,
rather than by stimulating NO synthase activity or by acting as
a substrate for NO synthesis (28). Another possibility is that
there is a relative deficiency of intracellular L-arginine created
by high doses of Ach. It has been suggested that in hypercho-
lesterolemic and hypertensive vessels, NO synthase activity is
up-regulated and the excessive NO produced in the vascular
endothelium is catabolized by superoxide anions, leading to a
net reduced bioavailability of NO to the vascular smooth
muscles (31–33). When NO activity is stimulated further by
Ach in these conditions, substrate deficiency may develop
intracellularly, which can be corrected by exogenous adminis-
tration of L-arginine.
The coronary vascular effects of high doses of Ach are
believed to result from its direct smooth muscle constricting
effects predominating over the dilator actions mediated by
endothelium-derived relaxing factors. In addition to smooth
muscle muscarinic receptor stimulation, Ach can stimulate
release of endothelium-dependent constrictors (34,35). Thus,
the effects of L-arginine, although assumed to be due to
increased production of NO, may theoretically also be nonspe-
cifically due to non-NO effects. These latter actions need to be
further explored with in vivo studies.
Improvement of Ach-mediated vasodilation with L-arginine
in humans. The observation that L-arginine improved Ach-
mediated vasodilation in hypercholesterolemic rabbits (10) led
to investigations of the effects of parenteral L-arginine in
human hypercholesterolemia. Although a similar improvement
in methacholine-mediated forearm microvascular dilation was
observed with intravenous L-arginine in hypercholesterolemic
Figure 5. Top, Coronary vascular resistance changes with cardiac
pacing before (solid circles) and after (open circles) L-arginine admin-
istration. Bottom, Effect of L-arginine on 19 epicardial coronary artery
segments that constricted with pacing (baseline diameter 2.47 6
1.0 mm) and on 35 dilating segments (baseline diameter 1.8 6
0.55 mm). Results are expressed as mean value 6 SEM.
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patients (11), improved Ach-mediated dilation was not ob-
served with intraarterial L-arginine in either hypercholester-
olemic or hypertensive patients (14,36). In contrast, improve-
ment of forearm vasodilation with Ach has been reported with
L-arginine in normal volunteers (14,16). Similar discrepancies
have been reported in the coronary vasculature. Although
Drexler et al. (13) reported improved Ach-mediated responses
in the hypercholesterolemic coronary vasculature and DuBois-
Rande´ et al. (22) reported the same in atherosclerotic coronary
vessels, Hirooka et al. (21) reported no improvement in
coronary vasodilation in either atherosclerotic or hypertensive
patients. These contrasting findings have been difficult to
explain and may stem, at least partly, from the small numbers
of patients studied, the variation in the doses of Ach used and
the differences in the amount and the route of L-arginine
administration.
Our study was conducted to investigate the effects of
L-arginine on the coronary vasculature of normal patients
without coronary risk factors, those with angiographically
normal coronary arteries and risk factors for atherosclerosis
and those with established atherosclerosis. The last two groups
are known to have abnormal vascular responses to Ach and
other endothelium-dependent vasodilators (37–39), an abnor-
mality that we recently demonstrated as being due to reduced
NO-induced coronary vasodilation (23–25). Although our re-
sults demonstrate an overall improvement in Ach-mediated
vasomotion in the patients tested, further analysis demon-
strated that the effect was most prominent at doses of Ach that
resulted in epicardial and microvascular constriction—that is,
when the capacity of Ach to stimulate NO release was ex-
ceeded by its stimulation of muscarinic receptors on vascular
smooth muscle. This was observed not only in patients with
atherosclerosis and those with risk factors for atherosclerosis at
lower doses of Ach, but also in subjects with normal coronary
arteries without risk factors in whom higher doses of Ach were
necessary to cause constriction. In this regard, our results are
similar to other studies where Ach-mediated coronary con-
striction was also reversed by L-arginine in patients with
atherosclerosis or hypercholesterolemia (13,19,22). Also, as
observed in our study, at lower doses of Ach that did not cause
coronary vasoconstriction, L-arginine did not improve coronary
vasodilation (21).
Metabolic coronary vasodilation and L-arginine. We have
previously shown that NO contributes to metabolic vasodila-
tion of the human coronary and peripheral circulation (24).
L-NG-monomethylarginine, the competitive antagonist of NO
synthase, inhibited coronary vasodilation in response to car-
diac pacing, forearm vasodilation in response to exercise (40)
and femoral vascular dilation in response to hyperemia (un-
published findings). Furthermore, we demonstrated that pa-
tients with atherosclerosis and its risk factors, who have
endothelial dysfunction measured as abnormal vasodilation in
response to Ach, had reduced vasodilation in response to
metabolic stress, and this in turn was secondary to a reduced
contribution of NO to metabolic coronary and peripheral
vasodilation. These observations confirmed in humans what
had been demonstrated in vitro and in animal studies regard-
ing the pivotal role of NO during shear-induced coronary and
peripheral vasodilation (41,42).
In this study, we investigated whether L-arginine, by increas-
ing NO availability during stress, could improve vasodilation in
response to cardiac pacing in patients with endothelial dys-
function. Our findings were that L-arginine reversed the epi-
cardial constriction that occurred during pacing in segments
with endothelial dysfunction, a finding that was consistent with
the effects of L-arginine on Ach-mediated epicardial constric-
tion. In contrast, microvascular vasodilation, even in patients
with atherosclerosis and its risk factors, did not improve
substantially with L-arginine. This latter observation is in
agreement with our previous studies on the effects of L-
arginine on peripheral metabolic vasodilation. Neither
exercise-induced forearm microvascular dilation (40) nor the
hyperemic microvascular dilation in atherosclerotic patients
was improved after intraarterial L-arginine (unpublished ob-
servations). Similarly, Adams et al. (18) reported a lack of
improvement in brachial artery flow-mediated vasodilation in
normal subjects after oral L-arginine therapy, although L-
arginine improves brachial artery vasomotion in hypercholes-
terolemic subjects (41). Studies where L-arginine was adminis-
tered orally or intravenously in patients with congestive heart
failure, a condition also characterized by endothelial dysfunc-
tion, have demonstrated improvement in systemic hemody-
namic data (17,20).
The discrepancies between the effects of L-arginine on
Ach-mediated microvascular constriction and metabolic vaso-
dilation are difficult to explain. However, because only a
relatively small percentage of metabolic coronary microvascu-
lar dilation during cardiac pacing is likely to be due to shear
stress-mediated NO release, then a small improvement in this
component with L-arginine may not be measurable clinically.
In contrast, flow-mediated conductance vessel dilation is
largely due to NO (24,42,43). Also, during physiologic stress
such as cardiac pacing, the stimulation of NO activity in the
coronary microvessels may not be as great as the maximal
stimulation with Ach, and thus microvascular L-arginine avail-
ability may not be rate-limiting during pacing, just as it appears
not to be rate-limiting during low dose infusions of Ach.
Specificity of L-arginine. We ensured that the vascular
actions of L-arginine in our study were specific for its effects as
a substrate for NO by also investigating the effects of D-
arginine, a stereoisomer of L-arginine that is not a substrate for
NO synthesis. D-Arginine produced no improvement in Ach-
mediated coronary epicardial or microvascular vasodilation.
We also studied the effects of L-arginine on endothelium-
independent vasodilation with adenosine and showed that this
remained unchanged after L-arginine. No baseline effects were
observed with L-arginine on systemic or coronary hemody-
namic data, indicating that the effects of local infusions of
L-arginine are not due to reflex changes.
Relation between effects of L-arginine and risk factors for
atherosclerosis. Because previous studies have demonstrated
an improvement of Ach-mediated vasodilation in hypercholes-
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terolemia (10,11,13), we investigated whether hypercholester-
olemia or any other risk factor, alone or in combination, was
related to the magnitude of improvement observed with L-
arginine, by performing a multiple stepwise regression analysis.
This demonstrated that the initial vascular effects of Ach, both
in the epicardial and microvascular circulations, were the most
important determinants of the subsequent response to L-
arginine. For epicardial vessels, cigarette smoking, which also
contributes to an initially abnormal response to Ach, was also
an independent determinant of the subsequent effect of L-
arginine. The improvement with L-arginine was greater at
doses of Ach that resulted in coronary vascular constriction,
and there appeared to be no direct relation between any other
risk factor and the response to L-arginine.
Study limitations. We did not administer high doses of
Ach to patients with atherosclerosis so as to avoid severe
epicardial coronary artery constriction. In a previous study,
higher doses of Ach were administered to patients with
coronary atherosclerosis, and it was demonstrated that patients
with more severely constricting arteries were the ones who
responded most dramatically to L-arginine (22).
Conclusions. L-Arginine improves both coronary vascular
constriction in response to the endothelium-dependent vaso-
dilator Ach and epicardial constriction in response to physio-
logic stress. Whether this beneficial effect of L-arginine, to-
gether with its antiplatelet aggregatory properties (18), will
reduce myocardial ischemia and thrombosis in patients with
atherosclerosis needs to be fully investigated.
We are grateful for the technical assistance of Gregory Johnson, William H.
Schenke and Rita Mincemoyer, RN.
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